Appl. No. 08/994,468 RCE filed October 21, 2004

2. Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-16. (Canceled)

Claim 17. (Previously presented) The hematopoietic cell expansion medium of claim 19, further comprising a cellular growth factor.

Claim 18. (Previously presented) The method according to claim 20, further comprising contacting the cells with a cellular growth factor.

Claim 19. (Currently amended) A hematopoietic cell expansion medium, comprising a cell growth medium and a:

- (a) a polypeptide comprising amino acids 28-160 of SEQ ID NO:6;
- (b) <u>a polypeptide comprising a fragment of amino acids 28-160 of SEQ ID NO:6,</u> wherein the fragment binds flt3; and
- (c) <u>a polypeptide</u> that binds flt3 that is at least 90% identical to amino acids 28-160 of SEQ ID NO:6.; or
- (d) fragment of (e), wherein the fragment binds flt3.

Claim 20. (Currently amended) An in vitro method for expanding hematopoietic cells, the method comprising contacting the cells with a:

- (a) a polypeptide comprising amino acids 28-160 of SEQ ID NO:6;
- (b) <u>a polypeptide comprising a fragment of acids 28-160 of SEQ ID NO:6,</u> wherein the fragment binds flt3; and
- (c) a polypeptide that binds flt3 that is at least 90% identical to amino acids 28-160 of SEQ ID NO:6; or
- (d) fragment of (e), wherein the fragment binds flt3;

in an amount sufficient to cause hematopoietic cell expansion.

Claim 21. (Previously presented) The hematopoietic cell expansion medium of claim 19, further comprising G-CSF.

Claim 22. (Previously presented) The hematopoietic cell expansion medium of claim 19, further comprising GM-CSF.

Claim 23. (Previously presented) The hematopoietic cell expansion medium of claim 19, further comprising SF.

Appl. No. 08/994,468 RCE filed October 21, 2004

Claim 24. (Previously presented) The hematopoietic cell expansion medium of claim 19, further comprising EPO.

Claim 25. (Previously presented) The hematopoietic cell expansion medium of claim 19, further comprising a GM-CSF/IL-3 fusion protein.

Claim 26. (Previously presented) The hematopoietic cell expansion medium of claim 19, further comprising IL-6.

Claims 27-30. (Cancelled)

Claim 31. (Previously presented) The method according to claim 20, further comprising contacting the cells with G-CSF.

Claim 32. (Previously presented) The method according to claim 20, further comprising contacting the cells with GM-CSF.

Claim 33. (Previously presented) The method according to claim 20, further comprising contacting the cells with SF.

Claim 34. (Previously presented) The method according to claim 20, further comprising contacting the cells with EPO.

Claim 35. (Previously presented) The method according to claim 20, further comprising contacting the cells with a GM-CSF/IL-3 fusion protein.

Claim 36. (Previously presented) The method according to claim 20, further comprising contacting the cells with IL-6.